Novavax Nuvaxovid COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older – Novavax Investor Relations
Posted By admin on September 18, 2022
Novavax Nuvaxovid COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
GAITHERSBURG, Md., Sept. 16, 2022 /PRNewswire/ -- Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine foractive immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines. The permit is based on the Israeli Advisory Committee on Epidemics' recommendation.
"Today's milestone provides the people of Israela protein-based COVID-19 vaccine developed using an innovative approach to traditional technology," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Nuvaxovid is now available for use in Israel in individuals aged 12 and older as both a primary series and a booster regardless of previous vaccine history."
Nuvaxovid has received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S.and from the World Health Organization.In the 12 through 17 year-old population, the vaccine has been authorized in more than 10 markets including the U.S., the European Union, and the United Kingdom. Nuvaxovid has also been authorized in the European Union, Japan, Australia, New Zealand, and Switzerlandas a booster in adults aged 18 and older. The vaccine is actively under review in other markets.
Trade Name in the U.S.
The trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.
Important Safety Information
For more information on Nuvaxovid, including the Summary of Product Characteristics with Package Leaflet, Prescribing Information and Important Safety Information, adverse event reporting instructions, or to request additional information, please visit the following website:
About Nuvaxovid (NVX-CoV2373)
Nuvaxovid (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. The vaccine was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Nuvaxovid contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2- 8 Celsius, enabling the use of existing vaccine supply and cold chain channels. Use of the vaccine should be in accordance with official recommendations.
Novavax has established partnerships for the manufacture, commercialization, and distribution of Nuvaxovid worldwide. Existing authorizations leverage Novavax' manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. They will later be supplemented with data from additional manufacturing sites throughout Novavax' global supply chain.
About the Novavax COVID-19 vaccine (NVX-CoV2373) Phase 3 Trials
The Novavax COVID-19 vaccine (NVX-CoV2373) continues being evaluated in two pivotal Phase 3 trials.
PREVENT-19 (thePRE-fusion protein subunitVaccineEfficacyNovavaxTrial | COVID-19) is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the efficacy, safety and immunogenicity of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 29,960 participants 18 years of age and over in 119 locations inthe U.S.andMexico. The primary endpoint for PREVENT-19 was the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second dose in serologically negative (to SARS-CoV-2) adult participants at baseline. The statistical success criterion included a lower bound of 95% CI >30%. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Both endpoints were assessed at least seven days after the second study vaccination in volunteers who had not been previously infected with SARS-CoV-2. In the trial, the Novavax COVID-19 vaccine achieved 90.4% efficacy overall. It was generally well-tolerated and elicited a robust antibody response after the second dose in both studies. Full results of the trial were published in theNew England Journal of Medicine(NEJM).
The pediatric expansion of PREVENT-19 is a 2:1 randomized, placebo-controlled, observer-blinded trial to evaluate the safety, effectiveness, and efficacy of the Novavax COVID-19 vaccine with Matrix-M adjuvant in 2,247 adolescent participants 12 to 17 years of age in 73 locations in the United States, compared with placebo. In the pediatric trial, the vaccine achieved its primary effectiveness endpoint (non-inferiority of the neutralizing antibody response compared to young adult participants 18 through 25 years of age from PREVENT-19) and demonstrated 80% efficacy overall at a time when the Delta variant of concern was the predominant circulating strain in the U.S.Additionally, immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied.
Additionally, a trial conducted in the U.K. with 14,039 participants aged 18 years and over was designed as a randomized, placebo-controlled, observer-blinded study and achieved overall efficacy of 89.7%. The primary endpoint was based on the first occurrence of PCR-confirmed symptomatic (mild, moderate or severe) COVID-19 with onset at least seven days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. Full results of the trial were published inNEJM.
About Matrix-M Adjuvant
Novavax' patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine, has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the WHO. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit http://www.novavax.com and connect with us on LinkedIn.
Forward-Looking Statements
Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, including an Omicron strain based vaccine and bivalent Omicron-based / original strain based vaccine, a COVID-seasonal influenza combination investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax' plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax' global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety intended utilization, and expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax' Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at http://www.sec.gov and http://www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
InvestorsErika Schultz | 240-268-2022ir@novavax.com
MediaAli Chartan or Giovanna Chandler | 202-709-5563media@novavax.com
SOURCE Novavax, Inc.
View original post here:
- 8 Palestinians said wounded in IDF raid in Jenin, clashes reported near Ramallah - The Times of Israel - May 29th, 2023
- Israeli airstrikes said to hit targets in Syrian capital - The Times of Israel - May 29th, 2023
- Why Netanyahu has put a halt to a handful of radical coalition measures for now - The Times of Israel - May 29th, 2023
- The Land of Hope and Fear review: vivid portrait of Israel in ferment - The Guardian - May 29th, 2023
- Israelis in NYC to protest coalition lawmakers in town for Celebrate Israel Parade - The Times of Israel - May 29th, 2023
- Even AIPAC would struggle to love the Israel seen in 'The Spy in ... - Haaretz - May 29th, 2023
- What will Israel spend on the environment this year? - The Jerusalem Post - May 29th, 2023
- Israel's IDF and Hezbollah's Nasrallah: Who is threatening whom and why? - The Jerusalem Post - May 29th, 2023
- We need to stop confronting Israeli propaganda on Israel's terms - Mondoweiss - May 29th, 2023
- Israel, Water and the Next 100 Years - Algemeiner - May 29th, 2023
- Israeli missing for two years reunited with family after being found in Jordan - The Times of Israel - May 29th, 2023
- Fathers from both sides of the Israel-Palestine conflict united by 'unbearable pain' - ABC News - May 29th, 2023
- Israels 3D printing firm XJet seeks to raise $10m from Nasdaq IPO - The Times of Israel - May 29th, 2023
- Israel Mukuamu might be the Cowboys most versatile DB in 2023 - Cowboys Wire - May 29th, 2023
- Play center in Harish becomes unlikely battleground for Haredi and secular residents - The Times of Israel - May 29th, 2023
- Tchau Israel! Tens of Thousands of Israelis Call This Country Their ... - Haaretz - May 29th, 2023
- 60% of Americans back reevaluating ties with Israel if judicial reform passes poll - The Times of Israel - May 24th, 2023
- Private diaries of 1948 generation offer 'authentic' history of Israel - The Jewish Chronicle - May 24th, 2023
- Israel's mixed cities: Jews still wealthier, although gaps are closing - The Jerusalem Post - May 24th, 2023
- Family building a house in northern Israel destroys 1,800-year-old burial cave - The Times of Israel - May 24th, 2023
- Russia says Zelensky heads Nazi regime with blood ties to Israel - The Times of Israel - May 24th, 2023
- Report: Israel nixed QuaDreams spyware deal with Morocco, leading to firms closure - The Times of Israel - May 24th, 2023
- UTJ MK: The government is not in our hands, Bank of Israel chief should quit - The Times of Israel - May 24th, 2023
- Madonna said set to visit Israel this weekend for Shavuot, but won't ... - The Times of Israel - May 24th, 2023
- Israel reportedly in advanced talks for direct flights to Hajj in Saudi Arabia - The Times of Israel - May 24th, 2023
- Its painful for us: Poland invites Noa Kirel for visit after Eurovision remarks - The Times of Israel - May 20th, 2023
- Woman run over and killed while crossing road in northern Israel - The Times of Israel - May 20th, 2023
- Tlaibs shameful weaponization of the Elie Wiesel Genocide Act against Israel - The Hill - May 20th, 2023
- US said to propose joint military planning with Israel on Iran, but Jerusalem wary - The Times of Israel - May 20th, 2023
- Governor Abbott Celebrates 75th Anniversary Of Israel's ... - Office of the Texas Governor - May 20th, 2023
- Israel draws fire from allies over Flag March, lawmakers visits to Temple Mount - The Times of Israel - May 20th, 2023
- Israel to invest $40 million in North American Jewish day schools - The Jewish News of Northern California - May 20th, 2023
- Israel Is Hurtling Toward a New Kind of Illiberal Regime - Israel News - Haaretz - May 20th, 2023
- The song that binds me to Israel | Sally Abrams | The Blogs - The Times of Israel - May 20th, 2023
- Israel's Eli Cohen aims to make more diplomatic breakthroughs than ever - The Jerusalem Post - May 20th, 2023
- Why is Israel so vital to the West? - Middle East Eye - May 20th, 2023
- Israel's operation in Gaza: A new level in precision fighting - opinion - The Jerusalem Post - May 20th, 2023
- This Irish immigrant to Israel has lived a life of courage and devotion - The Jerusalem Post - May 20th, 2023
- A harsh return to Israel after a blissful time in Italy - opinion - The Jerusalem Post - May 20th, 2023
- Israel: Pioneer Of The High-tech Industry, Zohar Zisapel, Dies At Age ... - i24NEWS - May 20th, 2023
- Israel looks to make history at mens U-20 soccer World Cup after Indonesia snub - The Times of Israel - May 20th, 2023
- Israel and Iranian people can fight the Iran regime together - opinion - The Jerusalem Post - May 20th, 2023
- Singer Nicole Raviv Honors Israel and Aims To Unite People With ... - Jewish Journal - May 20th, 2023
- The OECD's Herculean tax task and how it impacts Israel - The Jerusalem Post - May 20th, 2023
- Fingerhut reflects on JFNA GA in Israel - Cleveland Jewish News - May 20th, 2023
- Better Place: Israel's electric car start-up killed by its own success - The Jerusalem Post - May 20th, 2023
- Israel's biometric lab and its war against fraud at the borders - Ynetnews - May 20th, 2023
- BBC's 'disinformation' reporter should look at the way they cover Israel - The Jewish Chronicle - May 20th, 2023
- Scoop: U.S. proposed conducting joint military planning with Israel on Iran - Axios - May 17th, 2023
- US skips UN Nakba event marking dispossession of Palestinians after Israeli campaign - CNN - May 17th, 2023
- Hamas and Gazas incendiary balloon unit threaten to disrupt Jerusalem Flag March - The Times of Israel - May 17th, 2023
- Israel Has the Raw Military Power, but Palestinians Hold the Upper ... - Haaretz - May 17th, 2023
- Israel's Coalition and Opposition Nearing Agreements on Aspects of ... - Haaretz - May 17th, 2023
- What is Israel's role in the global gaming industry? - The Jerusalem Post - May 17th, 2023
- Iran is playing the long game against Israel, experts warn - JNS.org - May 17th, 2023
- Israel reopens Gaza crossings, shut since launch of Operation Shield and Arrow - The Times of Israel - May 17th, 2023
- Swedish party with Nazi roots wants to be friends of Israel, Jews - The Jerusalem Post - May 17th, 2023
- A house divided: New book explores roots of the rifts between Israels many tribes - The Times of Israel - May 17th, 2023
- The West is blind to the jihad against Israel - JNS.org - May 17th, 2023
- Israel, US, Cyprus and France to hold disaster preparedness event ... - Arutz Sheva - May 17th, 2023
- TASE and the SFI Group to launch first-of-its-kind Israel joint impact ... - PR Newswire - May 17th, 2023
- Daily Briefing May 17: Once hailed as Israels MLK, Ayman Odeh is leaving the Knesset - The Times of Israel - May 17th, 2023
- Israel, Islamic Jihad reach cease-fire after days of violence which ... - May 15th, 2023
- Ceasefire between Israel and Islamic Jihad in Gaza area takes effect ... - May 15th, 2023
- Cease-fire between Israel and militants in Gaza appears to hold - May 15th, 2023
- Israel - National Geographic Kids - May 15th, 2023
- Israel-Palestine: UN chief condemns killing of civilians as deadly Gaza ... - May 15th, 2023
- Abbas calls on UN to oust Israel at world bodys first Nakba Day commemoration - The Times of Israel - May 15th, 2023
- Israel wins Rest of World Vote during Eurovision grand final...followed by Finland and Armenia - wiwibloggs - May 15th, 2023
- Israel strikes Gaza homes of Palestinian Islamic Jihad militants ... - May 11th, 2023
- Kevin McCarthy blocks Rashida Tlaib from hosting 'antisemitic' event calling Israel a 'catastrophe' - Fox News - May 11th, 2023
- Israel protests continue for 18th consecutive week and other world news you may have missed - Yahoo News - May 11th, 2023
- Kevin McCarthy wants to use Israel's Netanyahu to embarrass Biden - MSNBC - May 3rd, 2023
- In Israel, son of last shah says Iranians absolutely ready for Israel ties - The Times of Israel - April 20th, 2023
- Hungary and Poland provide model for Israels assault on judiciary ... - April 16th, 2023
- Thousands of Israelis in new protests against judicial reforms - Al Jazeera English - April 16th, 2023
- Israel seeks US support for IDF buildup as expert predicts Iran strike ... - April 14th, 2023
- Israels President Sees Hope for Judicial Compromise - New York Times - April 14th, 2023
- Crises on multiple fronts threaten Benjamin Netanyahus grip on power - April 10th, 2023
- Tensions simmer in Jerusalem after Israel responds to rocket attacks with strikes on targets in Syria - NBC News - April 10th, 2023
Comments